<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02079974</url>
  </required_header>
  <id_info>
    <org_study_id>4169720110</org_study_id>
    <nct_id>NCT02079974</nct_id>
    <nct_alias>NCT02084667</nct_alias>
  </id_info>
  <brief_title>Statins: A New Therapeutic Option for Treatment of Patients With Endometriosis</brief_title>
  <official_title>Statins: A New Therapeutic Option for Treatment of Patients With Endometriosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Robert F. Casper</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Toronto Centre for Advanced Reproductive Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endometriosis is a chronic inflammatory disorder leading to painful periods, pain with
      intercourse and infertility. The available treatment options to alleviate pain involve mainly
      hormonal treatments and surgery. All current hormonal treatments are effective but disrupt
      the normal variations in reproductive hormones which prevent ovulation, and thus pregnancy.
      Statins, a group of cholesterol lowering drugs, have anti-inflammatory properties which may
      be helpful also for the pain related to endometriosis. The investigators plan to undertake a
      pilot study of 10 patients with endometriosis who will take pravastatin sodium together with
      coQ10, which is inhibited by statins, for a period of 3 months. If this pilot study shows
      that the statin treatment may decrease pain symptoms in endometriosis, then the investigators
      plan to undertake a larger study to further investigate this matter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Initial grading of pain by a Linear Analogue Scale (LAS) from 1-10

        -  Initial blood biochemistry including liver function test, lipid profile, creatine/BUN,
           creatine kinase

        -  3 months of treatment with statins (Pravastatin) in a dose of 40mg daily

        -  Supplementation with CoQ10 (200mg) daily for 3 months
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain</measure>
    <time_frame>3 months</time_frame>
    <description>Linear analogue scale for each component of pain (dysmenorrhea; pelvic pain; dyspareunia)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Pravastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pravastatin sodium 20mg PO daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>20 mg pravastatin sodium daily for 3 months</description>
    <arm_group_label>Pravastatin</arm_group_label>
    <other_name>pravastatin sodium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female patients of reproductive age group (18-38 years) with a clinical or surgical
             diagnosis of endometriosis with pain symptoms

        Exclusion Criteria:

          -  use of hormonal suppression for pain control (OCP, GnRHa) within 6-months

          -  history of surgery for endometriosis within 6- months

          -  current renal or hepatic active disease

          -  current or history of myopathic disease

          -  medication that may interact with statins (erythromycin, gemfibrosil, antifungals,
             antiretrovirals, other cholesterol lowering drugs)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Casper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Obstetrics and Gynecology, University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Hospital, University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2014</study_first_submitted>
  <study_first_submitted_qc>March 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2014</study_first_posted>
  <last_update_submitted>November 5, 2015</last_update_submitted>
  <last_update_submitted_qc>November 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Toronto Centre for Advanced Reproductive Technology</investigator_affiliation>
    <investigator_full_name>Dr. Robert F. Casper</investigator_full_name>
    <investigator_title>Professor, Dept of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>endometriosis</keyword>
  <keyword>pain</keyword>
  <keyword>fertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

